Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT01702558 (Clinical Trial/ Ado-Trastuzumab Emtansine)

Study Title
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer (NCT01702558)

Trial Description
This multicenter study will assess the maximum tolerated dose of capecitabine (Xeloda®;Genentech, Inc.) in combination with ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech, Inc.) in patients with HER2-positive metastatic breast cancer and in patients with HER2-positive locally advanced/metastatic gastric cancer using a Phase I design, followed by a randomized, open-label Phase II study to explore the efficacy and safety of the combination of Kadcyla and capecitabine compared with Kadcyla in metastatic breast cancer patients. The anticipated time on study treatment is until disease progression, intolerable toxicity, or withdrawal of consent.

This trial is sponsored by F. Hoffmann-La Roche. [1]

Study Data

  • Condition: 
    • Breast Cancer
    • Gastric Cancer
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 235
  • Start: December 2012
  • Estimated Completion: January 2017
  • Last verified: July 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: July 30, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar